Search

Displaying results 8111 - 8120 of 10000 in total
  1. Drug

    N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide

    go.drugbank.com/drugs/DB08559
    Experimental

    These are organic compounds containing the penicillin core structure, which is structurally characterized by a penam ring bearing two methyl groups at position 2, and an amide group at position 6 [starting … from the sulfur atom at position 1].

  2. Drug

    ZD4407

    go.drugbank.com/drugs/DB06539
    Experimental

    The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.

  3. Drug

    LB-P8

    go.drugbank.com/drugs/DB18535
    Investigational

    LB-P8 is an investigational live biotherapeutic product consisting of a single bacterial strain (_Leuconostoc citreum_).

  4. Drug

    Methylthioinosine

    go.drugbank.com/drugs/DB02896
    Experimental

    An analog of inosine with a methylthio group replacing the hydroxyl group in the 6-position.

  5. Drug

    5alpha-androstane-3beta,17alpha-diol

    go.drugbank.com/drugs/DB03926
    Experimental

    It has been implicated as a regulator of gonadotropin secretion. … 5alpha-androstane-3beta,17alpha-diol is the unspecified form of the steroid, normally a major metabolite of [testosterone] with androgenic activity.

  6. Drug

    NXN-188

    go.drugbank.com/drugs/DB06096
    Investigational

    NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

  7. Drug

    Cimicoxib

    go.drugbank.com/drugs/DB05095
    Investigational

    If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action. … Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia.

  8. Drug

    BGT-DTDS

    go.drugbank.com/drugs/DB18664
    Experimental

    It is under investigation for the treatment of dopamine transporter deficiency syndrome (DTDS). … BGT-DTDS is an investigational gene therapy comprising an adeno-associated viral vector type 2 (AAV2) encoding the human _SLC6A3_ gene.

  9. Drug

    AG0301-COVID19

    go.drugbank.com/drugs/DB15856
    Investigational

    The gene transfer method increases the efficiency of gene expression and antibody production capability, garnering a more efficient DNA vaccine product. … On September 8, 2020 AnGes announced collaboration with Brickell Biotech, Inc. following completion of Phase 1/2 clinical studies (NCT04463472).

  10. Drug

    Veltuzumab

    go.drugbank.com/drugs/DB05656
    Investigational

    Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.